Emerging strategies in the initial management of locally advanced rectal cancer
- PMID: 31424262
- DOI: 10.2217/fon-2018-0941
Emerging strategies in the initial management of locally advanced rectal cancer
Abstract
The initial management of locally advanced rectal cancer continues to evolve and formulating the ideal treatment plan remains challenging, with a multitude of emerging treatment strategies and either limited or inconsistent data to support these. The main objective of neoadjuvant treatment is to maximize disease control and minimize toxicity and impact on quality of life. Ultimately, the optimal approach needs to be personalized to the individual. In this Review, we discuss the various strategies currently used and being further investigated in the initial treatment of patients presenting with locally advanced rectal cancer. We describe the evidence behind the current standard of care recommendations and emerging new options, as well as potential biomarkers that may assist with further refining treatment selection.
Keywords: neoadjuvant therapy; rectal cancer; sequencing.
Similar articles
-
Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer.Future Oncol. 2014 Nov;10(14):2243-57. doi: 10.2217/fon.14.127. Future Oncol. 2014. PMID: 25471037 Review.
-
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.Oncologist. 2017 Jun;22(6):728-736. doi: 10.1634/theoncologist.2016-0396. Epub 2017 May 5. Oncologist. 2017. PMID: 28476941 Free PMC article. Clinical Trial.
-
The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.Oncotarget. 2015 Nov 10;6(35):38360-71. doi: 10.18632/oncotarget.5256. Oncotarget. 2015. PMID: 26451609 Free PMC article.
-
Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.Gut. 2019 Apr;68(4):663-671. doi: 10.1136/gutjnl-2017-315852. Epub 2018 Feb 2. Gut. 2019. PMID: 29420226 Free PMC article.
-
The Role of Circulating Tumor DNA for Management of Patients With Rectal Cancer: Challenges and Opportunities.Cancer J. 2024 Jul-Aug 01;30(4):290-296. doi: 10.1097/PPO.0000000000000731. Cancer J. 2024. PMID: 39042781 Review.
Cited by
-
Application of immune checkpoint inhibitors in colorectal cancer.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021 Aug 28;46(8):894-899. doi: 10.11817/j.issn.1672-7347.2021.200872. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021. PMID: 34565736 Free PMC article. Chinese, English.
-
Silencing eL31 suppresses the progression of colorectal cancer via targeting DEPDC1.J Transl Med. 2022 Oct 29;20(1):493. doi: 10.1186/s12967-022-03663-6. J Transl Med. 2022. PMID: 36309731 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources